S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

NMRA Neumora Therapeutics Inc

8.93

-0.22 (-2.40%)

Last Updated: 08:52:17

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Neumora Therapeutics (NASDAQ:NMRA)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more Neumora Therapeutics Charts.

Neumora Therapeutics (NASDAQ:NMRA)
Historical Stock Chart
From Jun 2023 to Jun 2024

Click Here for more Neumora Therapeutics Charts.

Neumora Therapeutics Inc News

Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
Thursday 20 June 2024 (3 hours ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 June 2024 (6 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 14 June 2024 (6 days ago) • Edgar (US Regulatory)

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Tuesday 14 May 2024 (1 month ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 7 May 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 7 May 2024 (1 month ago) • Edgar (US Regulatory)

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Tuesday 7 May 2024 (1 month ago) • GlobeNewswire Inc.

Neumora Therapeutics to Participate in Upcoming Conferences in May
Monday 6 May 2024 (1 month ago) • GlobeNewswire Inc.

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
Monday 15 April 2024 (2 months ago) • GlobeNewswire Inc.

Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
Wednesday 13 March 2024 (3 months ago) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Thursday 7 March 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 7 March 2024 (3 months ago) • Edgar (US Regulatory)

More Neumora Therapeutics Inc News Articles

Lyxor Index Fund-lyxor S...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions